Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer | Zendy

Mark Yarchoan | Zendy; Melinda C. Myzak | Zendy; Burles A. Johnson | Zendy; Ana De JesusAcosta | Zendy; Dung T. Le | Zendy; Elizabeth M. Jaffee | Zendy; Nilofer S. Azad | Zendy; Ross C. Donehower | Zendy; Lei Zheng | Zendy; Paul E. Oberstein | Zendy; Robert L. Fine | Zendy; Daniel A. Laheru | Zendy; Michael Goggins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

Author(s) -

Mark Yarchoan,

Melinda C. Myzak,

Burles A. Johnson,

Ana De JesusAcosta,

Dung T. Le,

Elizabeth M. Jaffee,

Nilofer S. Azad,

Ross C. Donehower,

Lei Zheng,

Paul E. Oberstein,

Robert L. Fine,

Daniel A. Laheru,

Michael Goggins

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.17237

Subject(s) - olaparib , irinotecan , medicine , pancreatic cancer , cisplatin , mitomycin c , oncology , gemcitabine , camptothecin , cancer research , chemotherapy , cancer , surgery , poly adp ribose polymerase , colorectal cancer , biology , biochemistry , polymerase , gene

Olaparib is an oral inhibitor of polyadenosine 5'-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research